The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S37-S44 , December 2006

Beyond Diuretics: Management of Volume Overload in Acute Heart Failure Syndromes

  • James A. Hill, MD

      Affiliations

    • Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA
    • Corresponding Author InformationRequests for reprints should be addressed to James A. Hill, MD, Division of Cardiovascular Medicine, University of Florida, 1600 Southwest Archer Road, Box 100277, Gainesville, Florida 32610.
    • ,
  • Clyde W. Yancy, MD

      Affiliations

    • Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA
    • ,
  • William T. Abraham, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohio State University, Columbus, Ohio, USA

References 

  1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). [published correction appears in J Am Coll Cardiol. 2006;47:1503–1505] J Am Coll Cardiol. 2005;46:e1–e82
  2. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416
  3. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother. 2004;38:649–660
  4. Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J. 2005;26:644–649
  5. Sackner-Bernstein JD. Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure. Curr Cardiol Rep. 2005;7:204–210
  6. Fonarow GC. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Failure Rev. 2004;9:179–185
  7. Cody RJ. Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol. 1993;22(suppl A):165A–171A
  8. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96:191–199
  9. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22
  10. Costello-Boerrigter LC, Boerrigter G, Burnett JC. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin North Am. 2003;87:475–491
  11. Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci. 1980;59:443–449
  12. Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987;60:1322–1328
  13. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6
  14. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387–395
  15. Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol. 1999;19:581–597
  16. Kidney Disease Outcomes Quality Initiative (K/DOQI) (K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease). Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  17. Anderson KP. Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. Ann Noninvasive Electrocardiol. 2003;8:75–89
  18. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331–338
  19. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther. 1997;62:187–193
  20. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28:376–382
  21. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  22. Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med. 1997;25:1969–1975
  23. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–67
  24. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail. 2003;9:13–25
  25. Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–580
  26. Wright SP, Verouhis D, Gamble G, Swedberg K, Sharpe N, Doughty RN. Factors influencing the length of hospital stay of patients with heart failure. Eur J Heart Fail. 2003;5:201–209
  27. Singh A, Blackwell J, Neher J. Does furosemide decrease morbidity or mortality for patients with diastolic or systolic dysfunction? [clinical inquiries]. J Fam Pract. 2005;54:370–372
  28. Mehta RL, Pascual MT, Soroko S, Chertow GM PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–2553
  29. Krämer BK, Schweda F, Riegger GAJ. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90–96
  30. Neuberg GW, Miller AB, O’Connor CM, et al. PRAISE Investigators Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–38
  31. Philbin EF, Cotto M, Rocco TA, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol. 1997;80:519–522
  32. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: ‘Guyton revisited.’. Eur Heart J. 2005;26:11–17
  33. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004;9:195–201
  34. Boerrigter G, Burnett JC. Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. Curr Heart Fail Rep. 2004;1:113–120
  35. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol. 2003;284:F11–F21
  36. Brater DC. Diuretic therapy in congestive heart failure. Congest Heart Fail. 2000;6:197–201
  37. Ravnan SL, Ravnan MC, Deedwania PC. Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail. 2002;8:80–85
  38. Iyengar S, Abraham WT. Diuretic resistance in heart failure. Curr Heart Fail Rep. 2006;3:41–45
  39. Bourge RC, Tallaj JA. Ultrafiltration: a new approach toward mechanical diuresis in heart failure. J Am Coll Cardiol. 2005;46:2052–2053
  40. Clark WR, Paganini E, Weinstein D, Bartlett R, Sheinfeld G, Ronco C. Extracorporeal ultrafiltration for acute exacerbations of chronic heart failure: report from the Acute Dialysis Quality Initiative. Int J Artif Organs. 2005;28:466–476
  41. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) Trial. J Am Coll Cardiol. 2005;46:2043–2046
  42. Costanzo MR, Saltzberg M, O’Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047–2051
  43. Jaski BE, Ha J, Denys BG, Lamba S, Trupp RJ, Abraham WT. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail. 2003;9:227–231
  44. Costanzo MR. Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) [ACC.06 smaller trial late-breaking clinical trials II]. Presented at the 55th Annual Scientific Sessions of the American College of Cardiology; March 11–14, 2006; Atlanta, Georgia. Available at: http://acc06online.acc.org/Lectures.aspx?sessionId=24&date=14. Accessed June 21, 2006.
  45. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001;38:963–968
  46. Rimondini A, Cipolla CM, Della Bella P, et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med. 1987;83:43–48
  47. Ramos R, Salem BI, DePawlikowski MP, et al. Outcome predictors of ultrafiltration in patients with refractory congestive heart failure and renal failure. Angiology. 1996;47:447–454
  48. Cuffe MS, Califf RM, Adams KFJ, et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  49. O’Connor CM, Gattis WA, Uretsky BF, et al. FIRST Investigators Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(pt 1):78–86
  50. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial. Circulation. 2004;110(suppl 3):III-515;Abstract 2415
  51. Abraham WT, Adams KF, Fonarow GC, et al. ADHERE Scientific Advisory Committee and Investigators and the ADHERE Study Group In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64
  52. Bennett SJ, Huster GA, Baker SL, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care. 1998;7:168–174
  53. Friedman MM. Older adults’ symptoms and their duration before hospitalization for heart failure. Heart Lung. 1997;26:169–176
  54. Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165–1172
  55. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol. 2002;39:1623–1629
  56. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–393
  57. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348:1756–1763
  58. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation. 1987;76:577–584
  59. Larsen AI, Goransson L, Aarsland T, Tamby JF, Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J. 1997;134:435–441
  60. Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004;93:237–240
  61. Adams KFJ, Mathur VS, Gheorghiade M. B-type natriuretic peptide: from bench to bedside. Am Heart J. 2003;145(suppl):S34–S46
  62. Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail. 2005;11:30–38
  63. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91–96
  64. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581–1588
  65. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens. 1996;9:432–436
  66. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004;109:1680–1685
  67. Mills RM, LeJemtel TH, Horton DP, et al. Natrecor Study Group Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 1999;34:155–162
  68. Colucci WS, Elkayam U, Horton DP, et al. Nesiritide Study Group Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–253
  69. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  70. Peacock WF, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J Emerg Med. 2005;29:243–252
  71. Saltzberg MT. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure. Rev Cardiovasc Med. 2004;5(suppl 4):S17–S27
  72. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  73. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905
  74. Gheorghiade M, Gattis WA, O’Connor CM, et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971
  75. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522–531
  76. Moiseyev VS, Põder P, Andrejevs N, et al. RUSSLAN Study Investigators Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422–1432
  77. Follath F, Cleland JG, Just H, et al. Steering Committee and Investigators of the Levosimendan infusion versus Dobutamine (LIDO) Study Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202
  78. Packer M. REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation. 2005;112:3363
  79. Mebazaa A. The SURVIVE-W Trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. Circulation. 2005;112:3364

PII: S0002-9343(06)01145-4

doi: 10.1016/j.amjmed.2006.09.015

The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S37-S44 , December 2006

Article Tools

* Image Usage & Resolution